Based on the new DNA strategy, the treatment of influenza virus shows hope

The Wistar Institute's MedImmune (AstraZeneca Global Biologics Research and Development Division) and Inovio Pharmaceuticals scientists have developed a novel, synthetic DNA-based strategy in preclinical models to provide protection against a variety of influenza viruses. These findings underscore this promising strategy, published in the npj vaccine.

Based on the new DNA strategy, the treatment of influenza virus shows hope

It is widely recognized that influenza strains change every year. Seasonal flu vaccines are effective against the annual flu virus. Therefore, at the end of the flu season, the vaccine must be put into production immediately for listing at the end of the summer.

“The process of discovery is not always smooth. Therefore, the vaccine available in the fall is not a good match for circulating strains, and the effect is poor,” said senior author David Weiner. The flu occasionally causes a dramatic change in the strain, leading to another strain of the virus, which requires a new vaccine development strategy that carries the risk of significant health consequences. "In addition, some vulnerable people may not respond well to vaccines, and the new, simple, rapid and widespread way to prevent the flu will be a big step forward."